Doctor’s Blog
Sav-Rx reverses denial of effective Adderall XR dose for my adult patient
Sav-Rx reversed its initial denial of my patient’s Adderall XR 80 mg daily after receiving my letter of appeal. In my letter, I highlighted the stable effective dose had been prescribed for quite sometime. Their initial reason for denial was a citing that FDA approved max daily dose was 60 mg in the morning. In […]
CVS/Caremark deny prescription for bogus reason
With each passing day, I encounter an increasing number of obstructions by insurance companies to authorize and provide my patients with their much needed medication. In my last blog, I highlighted Sav-Rx bogus reason to deny my patient the authorization to continue effective medication because of a change in policy coverage despite being on this dose for […]
SavRx disrupts effective ADHD treatment
With an increasing number of adults being nearly diagnosed with ADHD, the expense of ADHD medications for insurance companies has escalated. While the annual prescription increase for childhood ADHD is less than 3%, the ADHD prescription market is growing at approximately 10% per year. As a result of this change, companies are under increased pressure […]
Reliable ADHD information
If you’re reading this blog, you are one of the millions of people who now use the Internet to gain information on medical issues. In a recent survey of consumers, this is where people are looking for medical information. Most accessed online resources: 53% web M.D. 22% Wikipedia 19% health magazines and websites 16% advocacy […]
ADD stimulant substitution by insurance prohibited in Maryland
Step therapy is the requirement that a patient first try less costly medication before being prescribed medication a doctor thinks is best for the individual patient and specific symptoms/history. In the recent past, insurance companies had requested that adults with ADHD first be treated with a short-acting stimulant despite the fact that no short-acting stimulant […]
FDA looking into generic long-acting methylphenidates and variable effect
The following post from the FDA appeared today about complaints that generic long-acting methylphenidates (brand name-Concerta) may not work equally well. “In the case of the ADHD drug — certain generic versions of methylphenidate hydrochloride (Concerta, Janssen Pharmaceuticals) — the issue is a possible lack of therapeutic effect, which may be linked to product quality […]
Effexor XR and Venlafaxine ER RECALLED
Since many of my patients are on this antidepressant, I am posting the FDA warning issued this morning. Below is a copy of the text. Please see the link at the bottom of this blog for additional information. Effexor XR 150 Mg Extended-Release Capsules (Pfizer) and Venlafaxine HCl 150 Mg Extended-Release Capsules (Greenstone): Recall – […]
Dr. David W. Goodman invited to speak at Regional CHADD conference February 22, 2014 at West Chester University, PA
Anticipating over 300 attendees, the 13th Annual ADHD Conference for parents, teachers, professionals and adults with ADHD on Saturday, February 22, 2014 from 8:00am to 1:00pm will feature several expert speakers. West Chester University is just outside Philadelphia. Below is the program of speakers and topics. Marie Paxon, program coordinator, invited me to present on the science of […]
Dr. David W. Goodman “Ask the Expert” Webinar for the National Resource Center for ADHD, “The Representation of ADHD in the Media”
On February 5, 2014 Wednesday at 3:00pm, I will be providing a webinar on “The Representation of ADHD in the Media”. The webinar is sponsored by the National Resource Center for ADHD, supported by a grant for the Centers of Disease Control. The topic was chosen after a number of recent articles on ADHD in […]
Yes, you are losing medical benefits slowly and surely!
As time goes on, my patients are increasingly complaining about the loss of medication coverage or no longer affordable medication copays. Well, they are right and here is the proof. The following text was posted today by the American Medical Association with a link to Bloomberg News. Unfortunately, the public was never informed that the […]